Evidence-Based Hormonal Navigation Portal

Clear Answers for Your Hormones, Brain, and Body.

Perimenopausal hormone shifts can alter central nervous system signaling, sleep architecture, and metabolic regulation. OvaHarmony combines validated medical screening (MRS, PHQ-9, GAD-7, STRAW+10) with exact birth control interaction logic, transdermal safety data, and actionable doctor scripts.

Validated Medical Assessment

Menopause Rating Scale (MRS) Assessment

Completion 0%

Clinical Scale Overview: The Menopause Rating Scale (MRS) is an internationally validated 11-item diagnostic tool covering Somato-Vegetative, Psychological, and Urogenital symptom domains. Scores quantify quality-of-life impact to guide clinical management.

Rate symptom severity experienced over the past 30 days (0 = None to 4 = Very Severe). Click Learn More for exact physiological explanations.

The Physiological Blueprint Behind Your Symptoms

Fluctuating estrogen and progesterone levels during perimenopause alter neurochemical signaling across central and peripheral nervous system receptors. Understanding these biochemical mechanisms helps remove self-blame and focuses care on targeted physiological solutions:

Hypothalamic Thermoregulatory Dysfunction: 17β-estradiol stabilizes the KNDy (neurokinin B/dynorphin) neurons in the infundibular nucleus of the hypothalamus. Plunging estrogen causes uninhibited neurokinin-B signaling, narrowing the brain's thermoregulatory zone so minor environmental temperature changes trigger immediate flushing and profuse diaphoresis.
Neurosteroid & GABA-A Downregulation: Progesterone metabolizes into allopregnanolone, a potent positive allosteric modulator of GABA-A neuroreceptors in the amygdala. As ovulation becomes irregular, progesterone drops rapidly, causing acute GABA-A withdrawal characterized by unprovoked panic, heightened startle response, and severe 3 AM awakenings.
Serotonin & Mood Pathway Disruption: Estrogen upregulates tryptophan hydroxylase (the rate-limiting enzyme in serotonin synthesis) and downregulates monoamine oxidase (MAO-A), which degrades serotonin and dopamine. Estrogen withdrawal reduces synaptic serotonin density, precipitating emotional lability and low mood.
Cerebral Bioenergetic Shifts: 17β-estradiol is a master regulator of glucose transport (GLUT1/GLUT3) and ATP production in cerebral mitochondria. Transient estrogen drops reduce brain glucose metabolism by up to 20–25%, manifesting clinically as perimenopausal brain fog, memory retrieval lags, and mental fatigue.

Diagnostic Summary

Clinical Score Overview

MRS Total Score

0 / 44

Minimal Burden (0-4)

STRAW+10 Reproductive Stage

Late Reproductive (Stage -3)

Predictable cycles; subtle hormone shifts beginning.

Tailored Clinical Strategy:

• Complete symptom scoring on the left to generate customized medical, pharmacological, and lifestyle guidance.

Local Browser Analytics

Daily Symptom & Mood Trend Log

Single-day symptom snapshots can mislead clinicians due to perimenopausal hormone volatility. A 7-day rolling average provides accurate clinical baselines.

Log Date:

Vasomotor Episodes (24 hrs):

Total Sleep Duration (hrs):

Mood & Resilience Rating:

7-Day Avg Vasomotor Episodes 0.0

7-Day Avg Sleep Duration 0.0 hrs

7-Day Mood Baseline 0.0 / 5

7-Day Rolling Trend Line

Date	Vasomotor Count	Sleep Duration	Mood Level
No logged entries found. Use the form above to record daily data.

Diagnostic Integration

Birth Control & HRT Compatibility Matrix

Exogenous contraceptives alter ovarian suppression and uterine bleeding patterns. Standard sites rarely address how synthetic contraceptives interact with body-identical HRT.

Select Active Contraceptive Method:

Natural Cycles Selected

Endogenous gonadotropin signaling is unmasked. Cycle length shifts of ≥ 7 days accurately confirm STRAW Stage -2 (Early Perimenopausal Transition).

Method Type	Diagnostic & Bleeding Impact	Safe HRT Co-Administration?	Clinical Transition Protocol
Combined Pill / Patch / Ring (Ethinylestradiol)	Suppresses pituitary FSH/LH. Bleeds are synthetic withdrawal events, invalidating cycle tracking for menopause staging.	UNSAFE TO STACK	Adding HRT to COCP creates an excessively high estrogen load and elevated VTE risk. Must discontinue COCP under supervision or switch to Mirena IUD before starting body-identical HRT.
Levonorgestrel 52mg IUD (Mirena)	Local endometrial suppression causes light spotting or complete amenorrhea, but pituitary FSH/LH signaling remains active.	GOLD STANDARD PARTNER	Provides robust local uterine lining protection for up to 5 years (for HRT indications). Your clinician simply adds transdermal 17β-estradiol (patch or gel) without needing oral progesterone.
Progestin-Only Pill (POP)	Irregular breakthrough bleeding complicates tracking; does not consistently suppress ovulation depending on progestin type.	REQUIRES EVALUATION	Standard POP doses do not reliably guarantee endometrial protection against systemic transdermal estrogen. Clinicians usually add oral micronized progesterone or transition to Mirena.
Copper IUD / Barrier / Natural	Zero hormonal interference. Natural pituitary and ovarian cycles remain completely visible for staging.	FULLY COMPATIBLE	Ideal candidates for standard body-identical HRT regimens (transdermal 17β-estradiol plus oral micronized progesterone).

Evidence-Based Directory

Modern Bioidentical HRT, Testosterone & Progestogen Equivalence

Differentiating body-identical therapies from outdated synthetic options using official guidelines (NAMS, IMS, BMS).

Absolute & Relative HRT Contraindications Checklist

Absolute Contraindications (HRT Generally Avoided):

Current, past, or suspected breast cancer (estrogen-receptor positive)
Active or past hormone-dependent endometrial malignancy
Active or recent arterial thromboembolic disease (angina, myocardial infarction)
Active Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
Unexplained vaginal bleeding (must be investigated prior to HRT initiation)
Active acute liver disease with abnormal LFTs

Relative Contraindications (Requires Specialist Management):

Migraine with aura (oral estrogen contraindicated; transdermal gel/patch preferred)
Controlled hypertension or gallbladder disease
Severe active endometriosis (requires continuous progestogen protection)
High baseline risk of cardiovascular disease or stroke

Transdermal Estrogen

17β-Estradiol Patches & Gels

Molecularly identical to human ovarian estradiol. Bypasses hepatic first-pass metabolism to avoid elevating blood clotting factors. Observational data shows zero baseline elevation in VTE or stroke at standard doses (25–100 µg/day).

Uterine Protection

Oral Micronized Progesterone

Body-identical progesterone (Utrogestan / Prometrium) suspended in plant oil. Essential for endometrial protection. Metabolizes into allopregnanolone, stimulating GABA-A receptors for natural sedation when taken at bedtime (100mg continuous or 200mg sequential).

Androgen Protocol

Transdermal Testosterone Cream

Indicated for persistent Hypoactive Sexual Desire Disorder (HSDD) when systemic HRT alone falls short. Compounded or off-label female dosing (~1/10th male dose, e.g., 5mg/day gel) restores sexual arousal, motivation, and muscle protein synthesis.

Local Pelvic Care

Vaginal Estriol / Estradiol

Ultra-low-dose local creams or pessaries targeting Genitourinary Syndrome of Menopause (GSM). Rebuilds vaginal epithelial thickness, restores acidic pH (~3.8-4.5), and prevents recurrent UTIs with zero systemic absorption.

Progestogen Equivalence & Molecular Safety Breakdown

Progestogen Type	Molecular Structure	VTE & Breast Density Risk	Central Nervous System (Mood) Effects
Micronized Progesterone (Utrogestan)	Body-Identical (C₂₁H₃₀O₂)	Neutral VTE risk; lowest breast tissue proliferation	Metabolizes to neurosteroid allopregnanolone; promotes sleep architecture and calms amygdala reactivity.
Medroxyprogesterone Acetate (MPA)	Synthetic 17-hydroxyprogesterone derivative	Elevated breast density & VTE co-risk in clinical trials	Glucocorticoid receptor binding can trigger dysphoria, fluid retention, and blunted mood.
Norethisterone / Levonorgestrel (Oral)	Synthetic 19-nortestosterone derivative	Moderate risk profile; androgenic side effects	Partial androgenic binding; may trigger acne, oil production, or emotional irritability in sensitive patients.

Evidence Grading for Non-Prescription Supplements

Supplement & Dosing	Target Mechanism	Clinical Evidence Grade	Practical Guidance
Magnesium Glycinate (300–400mg elemental)	NMDA inhibition & GABA activation	High Evidence	Glycine chelate avoids digestive distress. Take at 8 PM to lower nocturnal cortisol, reduce muscle tension, and stabilize sleep.
Omega-3 Fatty Acids (1000mg EPA/DHA)	Downregulation of inflammatory eicosanoids (PGE2, IL-6)	Moderate Evidence	Alleviates estrogen-deficient joint stiffness (estrogenic arthralgia). Choose molecularly distilled triglycerides.
Creatine Monohydrate (3–5g daily)	Phosphocreatine brain bioenergetics & muscle protein synthesis	Emerging High Evidence	Counteracts cellular ATP depletion caused by low estrogen. Supports cognitive speed, memory retrieval, and lean muscle preservation.
Black Cohosh / Unregulated Botanicals	Serotonergic / phytoestrogenic modulation	Inconclusive / Caution	Mixed clinical trial results with documented risks of rare hepatotoxicity. Transdermal body-identical HRT remains superior in safety and efficacy.

Clear Answers for Your Hormones, Brain, and Body.

Menopause Rating Scale (MRS) Assessment

The Physiological Blueprint Behind Your Symptoms

Clinical Score Overview

Daily Symptom & Mood Trend Log

7-Day Rolling Trend Line

Birth Control & HRT Compatibility Matrix

Natural Cycles Selected

Modern Bioidentical HRT, Testosterone & Progestogen Equivalence

Absolute & Relative HRT Contraindications Checklist

17β-Estradiol Patches & Gels

Oral Micronized Progesterone

Transdermal Testosterone Cream

Vaginal Estriol / Estradiol

Progestogen Equivalence & Molecular Safety Breakdown

Evidence Grading for Non-Prescription Supplements

Doctor Conversation Kit & Medical Checklist

Word-for-Word Clinical Scripts

Essential Baseline Lab Checklist

Perimenopausal Mental Health & Global Crisis Support

Are You in Acute Emotional Distress or Crisis?

PMDD Overlay vs. Perimenopausal Rage

Sensory Grounding Protocol (5-4-3-2-1)

Personal Health Profile & Data Backup

Nutrition, Resistance Training & Sleep Protocols

Targeted Nutrition & Protein

High-Leverage Resistance Exercise

Vasomotor Trigger Mitigation

Sleep Architecture Protocol

International Medical Society Directory & Citations

The Menopause Society (NAMS)

International Menopause Society (IMS)

British Menopause Society (BMS)

Jean Hailes for Women's Health

Selected Peer-Reviewed Literature & Safety Studies